Mutation signatures implicate aristolochic acid in bladder cancer development

Genome Medicine

Volumn 7, Issue 1, 2015, Pages

  Poon, Ling S ^a,b   Huang, Ni M ^b   Choo, Yang ^b   McPherson, John R ^b   Yu, Willie ^a,b,c   Heng, Lee H ^a,b   Gan, Anna ^a,b   Myint, Swe S ^a,b   Siew, Yan E ^a,b   Ler, Dee L ^a,b,c   Ng, Guat L ^d   Weng, Wen Hui ^e   Chuang, Cheng Keng ^f   Yuen, John S P ^d   Pang, See Tong ^f   Tan, Patrick ^a,b,g,h   Teh, Tean B ^a,b,g   Rozen, Steven G ^b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

^e NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY   (Taiwan)

^f CHANG GUNG UNIVERSITY   (Taiwan)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^h GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ARISTOLOCHIC ACID;

ARTICLE; BLADDER CANCER; BLADDER TUMOR; CANCER GENETICS; CPG ISLAND; DRUG EXPOSURE; GENE IDENTIFICATION; GENE SEQUENCE; HERBAL MEDICINE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SOMATIC MUTATION;

EID: 84930195030     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/s13073-015-0161-3     Document Type: Article

References (57)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, et al. Cigarette smoking and bladder cancer in men: A pooled analysis of 11 case control studies. Int J Cancer. 2000;86:289-94.
3. Howe G, Burch J, Miller A, Cook G, Esteve J, Morrison B, et al. Tobacco use, occupation, coffee, various nutrients, and bladder cancer. J Natl Cancer Inst. 1980;64:701-13.
4. Bates MN, Smith AH, Hopenhayn-Rich C. Arsenic ingestion and internal cancers: a review. Am J Epidemiol. 1992;135:462-76.
5. Hopenhayn-Rich C, Biggs ML, Fuchs A, Bergoglio R, Tello EE, Nicolli H, et al. Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology. 1996;7:117-24.
6. Ward E, Carpenter A, Markowitz S, Roberts D, Halperin W. Excess number of bladder cancers in workers exposed to ortho-toluidine and aniline. J Natl Cancer Inst. 1991;83:501-6.
7. Ward EM, Sabbioni G, DeBord DG, Teass AW, Brown KK, Talaska GG, et al. Monitoring of aromatic amine exposures in workers at a chemical plant with a known bladder cancer excess. J Natl Cancer Inst. 1996;88:1046-52.
8. Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, et al. Carcinogenicity of some aromatic amines, organic dyes, and related exposures. Lancet Oncol. 2008;9:322-3.
9. International Agency for Research on Cancer. A Review of Human Carcinogens: Chemical Agents and Related Occupations. 2012. http://monographs.iarc.fr/ENG/Monographs/vol100F/mono100F.pdf .
10. Villanueva CM, Fernandez F, Malats N, Grimalt JO, Kogevinas M. Meta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancer. J Epidemiol Community Health. 2003;57:166-73.
11. Poon SL, McPherson JR, Tan P, Teh BT, Rozen SG. Mutation signatures of carcinogen exposure: genome-wide detection and new opportunities for cancer prevention. Genome Med. 2014;6:24.
12. Helleday T, Eshtad S, Nik-Zainal S. Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet. 2014;15:585-98.
13. Alexandrov LB, Stratton MR. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev. 2014;24:52-60.
14. Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P, et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med. 2013;5:197ra101.
15. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012;149:979-93.
16. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-21.
17. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214-8.
18. Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013;3:246-59.
19. Fischer A, Illingworth CJ, Campbell PJ, Mustonen V. EMu: probabilistic inference of mutational processes and their localization in the cancer genome. Genome Biol. 2013;14:R39. http://www.sanger.ac.uk/resources/software/emu .
20. Nordentoft I, Lamy P, Birkenkamp-Demtroder K, Shumansky K, Vang S, Hornshoj H, et al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep. 2014;7:1649-63.
21. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet. 2013;45:977-83.
22. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013;45:970-6.
23. Hoang ML, Chen CH, Sidorenko VS, He J, Dickman KG, Yun BH, et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med. 2013;5:197ra102.
24. Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A. 2012;109:8241-6.
25. Olivier M, Weninger A, Ardin M, Huskova H, Castells X, Vallee MP, et al. Modelling mutational landscapes of human cancers in vitro. Sci Rep. 2014;4:4482.
26. Moriya M, Slade N, Brdar B, Medverec Z, Tomic K, Jelakovic B, et al. TP53 Mutational signature for aristolochic acid: an environmental carcinogen. Int J Cancer. 2011;129:1532-6.
27. Hollstein M, Moriya M, Grollman AP, Olivier M. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. Mutat Res. 2013;753:41-9.
28. Chen CH, Dickman KG, Huang CY, Moriya M, Shun CT, Tai HC, et al. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int J Cancer. 2013;133:14-20.
29. Jelaković B, Castells X, Tomić K, Ardin M, Karanović S, Zavadil J. Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid. Int J Cancer. 2014. Epub ahead of print.
30. Scelo G, Riazalhosseini Y, Greger L, Letourneau L, Gonzàlez-Porta M, Wozniak MB, et al. Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat Commun. 2014;5:5135.
31. Lemy A, Wissing KM, Rorive S, Zlotta A, Roumeguere T, Martinez M-CM, et al. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am J Kidney Dis. 2008;51:471-7.
32. Li WH, Yang L, Su T, Song Y, Li XM. Influence of taking aristolochic acid-containing Chinese drugs on occurrence of urinary transitional cell cancer in uremic uremic patients undergoing dialysis. Zhonghua yi xue za zhi. 2005;85:2487-91.
33. Li XB, Xing NZ, Wang Y, Hu XP, Yin H, Zhang XD. Transitional cell carcinoma in renal transplant recipients: a single center experience. Int J Urol. 2008;15:53-7.
34. Shibutani S, Dong H, Suzuki N, Ueda S, Miller F, Grollman AP. Selective toxicity of aristolochic acids I and II. Drug Metab Dispos. 2007;35:1217-22.
35. Schmeiser HH, Schoepe KB, Wiessler M. DNA adduct formation of aristolochic acid I and II in vitro and in vivo. Carcinogenesis. 1988;9:297-303.
36. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet. 2013;45:1459-63.
37. The Cancer Genome Atlas. http://cancergenome.nih.gov/ .
38. The Cancer Genome Atlas Data Portal. https://tcga-data.nci.nih.gov/tcga/ _rfcollab The Cancer Genome Atlas Data Portal
39. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315-22.
40. Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44:765-9.
41. Burrows-Wheeler Aligner. http://bio-bwa.sourceforge.net/ .
42. European Genome-phenome Archive, https://www.ebi.ac.uk/ega/home .
43. EMu: Expectation-Maximisation inference of mutational signatures. http://www.sanger.ac.uk/resources/software/emu .
44. The R Project for Statistical Computing. http://www.r-project.org .
45. lsa: Latent Semantic Analysis. http://cran.r-project.org/web/packages/lsa/index.html .
46. Gokmen MR, Cosyns JP, Arlt VM, Stiborova M, Phillips DH, Schmeiser HH, et al. The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. Ann Intern Med. 2013;158:469-77.
47. Chau W, Ross R, Li JY, Yong TY, Klebe S, Barbara JA. Nephropathy associated with use of a Chinese herbal product containing aristolochic acid. Med J Aust. 2011;194:367-8.
48. Groopman JD, Cain LG, Kensler TW. Aflatoxin exposure in human populations: measurements and relationship to cancer. Crit Rev Toxicol. 1988;19:113-45.
49. Wogan GN. Aflatoxins as risk factors for hepatocellular carcinoma in humans. Cancer Res. 1992;52:2114s-8s.
50. Wild CP, Scalbert A, Herceg Z. Measuring the exposome: a powerful basis for evaluating environmental exposures and cancer risk. Environ Mol Mutagen. 2013;54:480-99.
51. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 2008;74:158-69.
52. Grollman AP. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen. 2013;54:1-7.
53. Heinrich M, Chan J, Wanke S, Neinhuis C, Simmonds MS. Local uses of Aristolochia species and content of nephrotoxic aristolochic acid 1 and 2-a global assessment based on bibliographic sources. J Ethnopharmacol. 2009;125:108-44.
54. Michl J, Jennings HM, Kite GC, Ingrouille MJ, Simmonds MSJ, Heinrich M. Is aristolochic acid nephropathy a widespread problem in developing countries? A case study of Aristolochia indica L. in Bangladesh using an ethnobotanical-phytochemical approach. J Ethnopharmacol. 2013;149:235-44.
55. NTP (National Toxicology Program). Report on Carcinogens. 13th ed. Research Triangle Park, NC: U.S: Department of Health and Human Services, Public Health Service; 2014. http://ntp.niehs.nih.gov/pubhealth/roc/roc13/ .
56. Marcus DM, Grollman AP. The consequences of ineffective regulation of dietary supplements. Arch Intern Med. 2012;172:1035-6.
57. U.S. Food and Drug Administration. Aristolochic Acid: Safety Alert; 2014. http://www.fda.gov/Food/RecallsOutbreaksEmergencies/SafetyAlertsAdvisories/ucm095272.htm